Indolent Lymphoma
News
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myeloma
Key clinical point: The CUDC-907 dose to be used in phase II studies will be 60 mg on a 5-days-on/2-days-off dosing schedule. Major finding: Two...
News
FDA approves venetoclax for CLL with 17p deletion
News
OTX015 dose for lymphoma narrowed in phase 1 study
Key clinical point: For lymphoma patients, a regimen has been determined for the small-molecule inhibitor OTX015 that was associated with...
News
Feds advance cancer moonshot with expert panel, outline of goals
Possible opportunities include vaccine development, early-detection technology, single-cell genomic analysis, immunotherapy, a focus on pediatric...
News
Idelalisib use halted in six combo therapy trials, FDA announces
News
Follicular lymphoma: Quantitative PET/CT measures for detecting bone marrow involvement
Key clinical point: Measuring the mean standardized uptake value of 18fluorodeoxyglucose in the bone marrow of patients with follicular lymphoma...
News
Expert panel issues guidelines for treatment of hematologic cancers in pregnancy
The guidelines aim to ensure that timely treatment of the cancers is not delayed in pregnant women. While rare, hematologic malignancies in...
Conference Coverage
New therapies finding their place in management of follicular lymphoma
News
Medical Roundtable: Hodgkin Lymphoma - Discussing Recent Evidence & Practice Options
News
Obinutuzumab trends better than rituxumab in relapsed indolent lymphoma
Key clinical point: Obinutuzumab was associated with a higher overall response rate as compared with rituximab, but obinutuzumab’s clinical...
News
Lenalidomide + rituximab combo effective in recurrent follicular lymphoma
Key clinical point: Lenalidomide combined with rituximab is more active in recurrent follicular lymphoma, compared with lenalidomide monotherapy....